Compare
Abeona Therapeutics Inc. vs Puma Biotechnology, Inc. vs Evommune, Inc. vs Pliant Therapeutics, Inc.
| Latest fiscal year | Abeona Therapeutics Inc. ABEORevenue covers only part of its income (partial revenue) | Puma Biotechnology, Inc. PBYI | Evommune, Inc. EVMN | Pliant Therapeutics, Inc. PLRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $228.37M | $13.00M | $0 |
| Revenue growth (YoY) | n/a | -0.9% | +85.7% | n/a |
| Gross margin | n/a | 74.5% (computed) | n/a | n/a |
| Operating margin | n/a | 16.3% | -623.6% | n/a |
| Net margin | n/a | 13.6% | -529.8% | n/a |
| Net income | $71.18M | $31.11M | -$68.87M | -$149.34M |
| EPS (Diluted) | $1.01 | $0.61 | -$11.22 | -$2.43 |
| Operating cash flow | -$76.33M | $41.80M | -$76.44M | -$128.34M |
| Free cash flow | -$84.30M | $41.73M | -$76.68M | -$128.71M |
| Cash & equivalents | $78.44M | $29.64M | $44.06M | $45.45M |
| Total assets | $219.57M | $216.30M | $224.95M | $225.23M |
| Total liabilities | $60.35M | $85.96M | $19.38M | $44.02M |
| Shareholders' equity | $159.22M | $130.34M | $205.57M | $181.21M |
| Return on year-end equity | 44.7% | 23.9% | -33.5% | -82.4% |
| Shares outstanding | 55.04M | 50.41M | 31.52M | 61.45M |
Revenue, most recent five fiscal years
| Fiscal year | Abeona Therapeutics Inc. | Puma Biotechnology, Inc. | Evommune, Inc. | Pliant Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $228.37M Ended 2025-12-31 | $13.00M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $230.47M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $235.64M Ended 2023-12-31 | n/a | $1.58M Ended 2023-12-31 |
| 3 years earlier | n/a | $228.03M Ended 2022-12-31 | n/a | $9.69M Ended 2022-12-31 |
| 4 years earlier | n/a | $253.16M Ended 2021-12-31 | n/a | $7.57M Ended 2021-12-31 |